Comment
doi: 10.1007/s00280-016-3044-4.
Epub 2016 May 13.
Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?
Affiliations
- PMID: 27178178
- DOI: 10.1007/s00280-016-3044-4
Item in Clipboard
Comment
Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?
Cancer Chemother Pharmacol.
2016 Nov.
No abstract available
Comment in
-
15-0600-Dr. Fox's response to letter to the editor.Cancer Chemother Pharmacol. 2016 Nov;78(5):1099-1100. doi: 10.1007/s00280-016-3162-z. Epub 2016 Oct 11. Cancer Chemother Pharmacol. 2016. PMID: 27730303 Free PMC article. No abstract available.
Comment on
-
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.Cancer Chemother Pharmacol. 2015 Dec;76(6):1273-83. doi: 10.1007/s00280-015-2845-1. Epub 2015 Oct 20. Cancer Chemother Pharmacol. 2015. PMID: 26486517 Free PMC article. Clinical Trial.
Similar articles
-
A Prediction Method for P-glycoprotein-Mediated Drug-Drug Interactions at the Human Blood-Brain Barrier From Blood Concentration-Time Profiles, Validated With PET Data.J Pharm Sci. 2017 Sep;106(9):2780-2786. doi: 10.1016/j.xphs.2017.03.024. Epub 2017 Apr 4. J Pharm Sci. 2017. PMID: 28385544
-
Increasing nerve agent treatment efficacy by P-glycoprotein inhibition.Chem Biol Interact. 2016 Nov 25;259(Pt B):115-121. doi: 10.1016/j.cbi.2016.06.012. Epub 2016 Jun 7. Chem Biol Interact. 2016. PMID: 27287416
-
Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.Int J Cancer. 2003 Jan 1;103(1):121-5. doi: 10.1002/ijc.10792. Int J Cancer. 2003. PMID: 12455064
-
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59. doi: 10.1586/14737140.7.4.447. Expert Rev Anticancer Ther. 2007. PMID: 17428165 Review.
-
Immunosuppressors as multidrug resistance reversal agents.Methods Mol Biol. 2010;596:433-46. doi: 10.1007/978-1-60761-416-6_19. Methods Mol Biol. 2010. PMID: 19949935 Review.
Cited by
-
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein.Science. 2019 Feb 15;363(6428):753-756. doi: 10.1126/science.aav7102. Science. 2019. PMID: 30765569 Free PMC article.
-
A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking.Cells. 2019 Oct 21;8(10):1286. doi: 10.3390/cells8101286. Cells. 2019. PMID: 31640190 Free PMC article.
-
Mode of Action Analyses of Neferine, a Bisbenzylisoquinoline Alkaloid of Lotus (Nelumbo nucifera) against Multidrug-Resistant Tumor Cells.Front Pharmacol. 2017 May 5;8:238. doi: 10.3389/fphar.2017.00238. eCollection 2017. Front Pharmacol. 2017. PMID: 28529482 Free PMC article.
-
Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):915-933. doi: 10.1007/s13318-017-0411-4. Eur J Drug Metab Pharmacokinet. 2017. PMID: 28374336 Review.
-
Residues from Homologous Transmembrane Helices 4 and 10 Are Critical for P-Glycoprotein (ABCB1)-Mediated Drug Transport.Cancers (Basel). 2023 Jul 1;15(13):3459. doi: 10.3390/cancers15133459. Cancers (Basel). 2023. PMID: 37444569 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
